Dyslipidemia is the hallmark of the metabolic syndrome in postmenopausal women: Dyslipidemia in postmenopausal women by Osman, Asim Alaaeldin & Fadlalla, Ahmed Mohamed
 A n n  M e d  P h y s i o l .  2 0 2 0 ;  4  ( 2 ) : 1 8 - 2 1   
 
Q u e n c h  A c a d e m y  o f  M e d i c a l  E d u c a t i o n  a n d  R e s e a r c h  
A n n a l s  o f  M e d i c a l  P h y s i o l o g y  
w w w . a m p h y s i o l . c o m  
 
 
 
Corresponding author 
 
 
 
Dr. Asim Alaaeldin Osman DOI: https://doi.org/10.23921/amp.2020v4i2.115684 
 Print ISSN: XXXX-XXXX 
Department of Human Physiology, 
Faculty of Medicine and Health Sciences, 
University of Gadarif, Gadarif, Sudan. 
Online ISSN: 2456-8422 
Copyright © 2020. Quench Academy of Medical Education and 
Research (QAMER). 
Phone: + 249-914612397 
 
This is an open access article licensed under a 
Creative Commons Attribution 4.0 International 
License. Email: asim9517@gmail.com 
    18 
 
Original Research Article 
Dyslipidemia is the hallmark of the metabolic 
syndrome in postmenopausal women 
Asim Alaaeldin Osman1 , Ahmed Mohamed Fadlalla2 
1
Department of Human Physiology, Faculty of Medicine and Health Sciences, University of Gadarif, 
Gadarif, Sudan. 
2
Department of Physiology, Faculty of Medicine, International University of Africa, Khartoum, Sudan. 
Article history  Abstract 
Received 16 June 2020 
Revised 19 June 2020 
Accepted 30 June 2020 
Online 30 June 2020 
Print 30 June 2020 
 
The incidence of cardiovascular diseases (CVD) increases after menopause 
and may be due to changes in the plasma lipid-lipoprotein levels that occur 
following menopausal transition. Physiological estrogen withdrawal during 
menopause plays a major role in abnormal lipid metabolism such as 
elevated low-density lipoprotein concentration. The aim of this study was to 
determine the relationship between dyslipidemia and the causative factors 
of metabolic syndrome in postmenopausal women. In this cross-sectional 
study, 290 postmenopausal Sudanese women were included. Lipid profiles 
were measured by spectrophotometer, estrogen hormone determined by 
ELISA, insulin resistance determined by HOMA-2 calculator and lipid 
accumulation product was calculated by the following equation (waist 
circumference in cm X triglyceride concentration in mM). The results 
revealed that total cholesterol, triglycerides, low-density lipoprotein levels 
and very low-density lipoprotein levels were significantly higher in the 
postmenopausal women with metabolic syndrome (MS) in comparison to 
those without the MS. Elevated total cholesterol levels were seen in 51.7 %, 
elevated triglycerides were seen in 49.7% and elevated low-density 
lipoprotein levels were seen in 29.3% whereas reduced high density 
lipoprotein levels were seen in 16.89% of the postmenopausal women. Total 
cholesterol, triglycerides and very low-density lipoprotein values showed a 
significant positive correlation with insulin resistance and lipid accumulation 
and a significant negative correlation with the estrogen hormone level. In 
addition, high density lipoproteins showed a significant negative correlation 
with lipid accumulation levels. 
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Introduction 
Dyslipidemia is a major risk factor cardiovascular 
disease (CVD) that represents the main cause of 
death among postmenopausal women [1]. High 
level of total cholesterol (TC), low-density 
lipoprotein (LDL) and triglycerides (TG) are seen 
frequently in postmenopausal women (PMW) [2]. 
Observational studies that were carried out to 
compare lipid profile in women showed a slight but 
significant reduction in the high density lipoprotein 
(HDL) as well as an increase in TG and LDL levels 
in postmenopausal women when compared to 
premenopausal women [3]. However, Kuller et al 
observed that the LDL concentrations remain 
constant in women during menopausal transition, 
in addition they documented that in 
postmenopausal women with very low blood 
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estrogen level the HDL2 fraction and Apoprotein 
A-1 decreased significantly [4]. Dyslipidemia of MS 
occur secondary to enlargement of abdominal 
adipose tissue that increases the blood free fatty 
acids level which consequently leads to raised TG 
values, low HDL values and increased LDL values. 
Dyslipidemia in MS patients might occur as a 
direct consequence of a global metabolic effect of 
insulin resistance that is characterized by 
excessive production of very low density 
lipoprotein (VLDL) and increased catabolism of 
HDL particles [5]. 
Materials and methods 
This descriptive cross-sectional study was 
conducted in the Gadarif State, Sudan. The study 
was permitted by Ethical Committee of the Faculty 
of Medicine and Health Sciences, University of 
Gadarif (Reference number: DOP 4-2018). 
Informed consent was obtained from each 
participant. 
Subjects 
Two hundred and ninety postmenopausal women 
were included, whose ages ranged between 45 
and 70 years. In this study menopause was 
diagnosed when a woman has not menstruated for 
at least one year. 
Methodology 
Fasting blood sample was collected. Lipid profile 
and fasting blood glucose were measured by using 
spectrophotometer kits (Biosystems S.A., 
Barcelona, Spain).  
Estrogen hormone determined by using the ELISA 
estradiol E2 kit (Immunometrics (UK) Ltd., London, 
UK).  
Waist circumference in centimetres (WC) 
measured by placing tape measure halfway 
between the bottom of lowest rib and the top of hip 
bones on light clothes. Blood pressure was 
measured by sphygmomanometer.   
Lipid accumulation product (LAP): LAP calculation 
equation is based on a combination of WC and 
plasma TG level. Specific LAP for women = (WC 
[cm]−58) × (TG concentration [mM]). Insulin 
resistance determined by HOMA-2 calculator. 
Metabolic syndrome was diagnosed by using 
updated diagnostic criteria adopted by National 
Cholesterol Education Program (NCEP) Adult 
Treatment Panel III (ATPIII) that defines the MS as 
three or more of five abnormalities 
1. Waist circumference of > 35 inches (88 cm) for 
females. 
2. Triglycerides level of > 150 mg/dl. 
3. High density lipoprotein cholesterol of < 50 
mg/dl in women. 
4. Blood pressure of > or = 130/85 mmHg. 
5. Fasting glucose of > or = 110 mg. 
Dyslipidemia diagnosed by using updated 
diagnostic criteria adopted by NCEP-ATPIII that 
defined dyslipidemia as: TC> 200 mg/dl, LDL-C > 
100 mg/dl and TG >150mg/dl. 
Statistical analysis 
Statistical analyses were performed by SPSS 
version 25 (IBM SPSS Inc., Chicago, IL, USA). 
Descriptive statistics was employed in this study, 
results presented as means ± standard deviations 
(Mean ± SD). Independent samples t-test was 
conducted to compare the relationship between 
dyslipidemia and MS. Pearson correlation was 
computed to estimate associations between the 
variables.  P value less than 0.05 was considered 
significant.  
Results  
Results are presented in the Table 1 showing that 
total cholesterol, TG, LDL and VLDL were 
significantly higher in the postmenopausal women 
with MS relative to the group without MS 
(p=0.000). HDL was significantly low in the 
postmenopausal women with MS (p=0.011). 
Table 1: Comparison of lipid profile between PMW 
with and without MS 
Lipid 
profile   
PMW with MS 
(n= 149) 
PMW without  
MS (n=141) 
P value 
TC 
(mg/dl) 
208.75±50.22 183.79±44.65 0.000 
TG 
(mg/dl) 
209.49±85.12 125.54±51.19 0.000 
HDL 
(mg/dl) 
80.35±38.15 90.82±31.59 0.011 
LDL 
(mg/dl) 
87.48±40.87 69.47±37.20 0.000 
VLDL 
(mg/dl) 
41.20±17.83 25.06±10.50 0.000 
Table 2 shows the prevalence of dyslipidemia 
among postmenopausal women. More than one-
half of the subjects (n=150) had elevated TC levels 
(51.7%). Elevated TG levels were seen in 49.7% 
(n=144) of the subjects. Elevated LDL levels were 
seen in 29.3% (n=85) of the subjects. Reduced 
HDL levels were seen in 16.9% (n=49) of the 
subjects.  
Table 2: Prevalence of dyslipidemia PMW women 
Dyslipidemia N=290 % 
TC ≥200 mg/dl 150 51.7 
TAG ≥150mg/dl 144 49.7 
LDL ≥100 mg/dl 85 29.3 
HDL ≤50mg/dl (F) 49 16.9 
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Table 3 shows that TC, TG and VLDL values 
positively correlated with insulin resistance and 
LAP; on the other hand negatively correlated with 
estrogen level. HDL significantly negatively 
correlated with LAP.  
Table 3: Correlation of lipid profile with estrogen 
hormone level, insulin resistance (HOMA2-IR) and 
LAP in postmenopausal women 
Parameters Statistics 
(Pearson 
correlation) 
Estrogen HOMA2
-IR 
LAP 
TC r -0.271 0.227 0.242 
p (2 tailed) 0.000 0.000 0.000 
TG r -0.342 0.336 0.870 
p (2 tailed) 0.000 0.000 0.000 
HDL r -0.040 0.050 -0.170 
p (2 tailed) 0.496 0.396 0.004 
LDL r -0.154 0.096 0.117 
p (2 tailed) 0.009 0.101 0.046 
VLDL r -0.314 0.303 0.778 
p (2 tailed) 0.000 0.000 0.000 
 
Discussion 
Our study revealed that TC, TG, LDL and VLDL 
were significantly higher in the postmenopausal 
women with MS in comparison to those without the 
MS; this is in agreement with several previous 
studies [6,7]. HDL levels were significantly lower 
among postmenopausal women with MS which 
approved with findings reported by Adam et al [8]. 
In our study, the postmenopausal women had 
hyperlipidemia which contributes to development 
of MS in these women this is in agreement with 
the finding documented by Genest [9]. 
Possible causes of dyslipidemia include visceral 
obesity and insulin resistance. Enlarged visceral 
adiposity causes adipose tissues hypertrophy 
which reduces fatty acid trapping, this increase the 
hepatic uptake of free fatty acid [10], this leads to 
excessive production of TG, which in turn increase 
the secretion of VLDL in the liver [11]. 
Enlargement of visceral adiposity in 
postmenopausal women occurs mainly due to 
reduced endogenous estrogen. The state of 
hypoestrogenism that occur in postmenopausal 
women would contribute in the development of 
dyslipidemia most probably by redistribution of fats 
from periphery to the abdomen [12] and  by 
reduction in the normal dyslipidemic effect of 
estrogen that include up-regulation of LDL 
receptors [13]. Among our study population, 
estrogen hormone significantly negatively 
correlated with the TC, TG, LDL and VLDL, 
indicating the major role played by 
hypoestrogenism for the development of 
dyslipidemia. In addition, LAP which represent 
enlarged adiposity, significantly positively 
correlated with TC, TG, LDL and VLDL, and 
negatively correlated with HDL. These findings 
directly explain the role of enlarged central 
adiposity in the development of dyslipidemia 
among postmenopausal women. 
The state of insulin resistance that occurs in the 
postmenopausal women with MS regarded as a 
trigger factor for development of dyslipidemia. In 
the presence of insulin resistance the visceral 
adipocytes fail to respond to lipolytic effect of 
insulin, so that large amount of free fatty acids 
released into the hepatic cells leading to 
disproportionate production of TG and TG rich 
VLDLs [14] which consequently leads to increased 
production of apo-B — the major protein of LDL 
[15].  In the present study insulin resistance 
positively correlated with TC, TG and VLDL 
confirming the central role of insulin resistance 
state in the development of dyslipidemia and 
metabolic syndrome in our subjects. 
Conclusion 
Postmenopausal hyperlipidemia occurs as a direct 
consequence of metabolic syndrome due to state 
of hypoestrogenism that leads to enlargement of 
central adiposity and insulin resistance. It warrants 
management of these conditions which will 
prevent the development of CVD in 
postmenopausal women. 
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